Europe's Brewing Revolution: Mycelium Protein Transforms Industrial Assets
June 1, 2026, 3:37 pm
Location: Germany
Total raised: $12.25M
Pacifico Biolabs secured €7 million Series A funding. The company scales mycelium protein production. It repurposes underutilized European brewery infrastructure. This innovative model offers sustainable, cost-effective alternative protein. It reduces environmental impact. It bolsters regional food security. Retail launches are slated for late 2026. This move reshapes food production.
Berlin-based Pacifico Biolabs announced significant financing. A €7 million Series A round closed. This investment fuels ambitious expansion plans. The company accelerates its mycelium protein production platform. It solidifies its position in the rapidly expanding alternative protein market. This milestone marks a pivotal moment for the food technology startup. It prepares for a major commercial launch.
Pacifico Biolabs addresses critical food system challenges. Global demand for sustainable food grows. Resource-efficient production is paramount. The company develops protein products from mycelium. Mycelium forms the root-like structure of fungi. It is a powerful ingredient. A fermentation-based process is key. This biotechnology yields high-quality protein ingredients. It dramatically lowers environmental footprints. Traditional animal agriculture carries heavy costs. Mycelium protein requires less land. It uses less water. It emits fewer greenhouse gases. Pacifico Biolabs offers a superior path. It combines biotechnology with existing industrial assets. This creates scalable protein solutions. These solutions can meet future global food needs.
The newly secured capital drives core strategies. Production capabilities will expand. This leverages proprietary fermentation technology. The system operates within existing brewery facilities. This is a game-changing approach. Pacifico Biolabs avoids new construction. It partners with breweries. These facilities often possess idle fermentation capacity. Europe's beer consumption trends decline. Breweries seek new revenue streams. Pacifico Biolabs provides a symbiotic solution. It repurposes existing industrial assets. This model slashes capital expenditures. It shortens market timelines significantly. It enables swift deployment of sustainable protein. Products reach consumers faster. This is efficient industrial synergy.
The Series A round attracted a strategic group of investors. They focus on food innovation. Sustainability drives their decisions. Biotechnology represents their future vision. Stray Dog Capital joined the round. TGFS Technologiegründerfonds Sachsen invested. Sprout & About Ventures contributed. Simon Capital and FoodLabs also participated. A regional brewery partner demonstrated confidence. This syndicate underscores growing market interest. Technologies improving food system resilience are in demand. Environmental and supply chain challenges demand solutions. Pacifico Biolabs provides clear answers. Its technology promises a more secure food future.
Funding supports several strategic initiatives. These drive the company’s next growth phase. Increasing production capacity is primary. This focuses on scaling operations in Saxony, Germany. Expanding the workforce is critical. New talent will join R&D and commercial teams. Research and development efforts will strengthen. This enhances product formulation and process efficiency. Commercialization activities will advance across key European markets. The DACH region (Germany, Austria, Switzerland) is a primary focus. Nordic Europe also represents a vital target. These markets show strong consumer interest in sustainable food options.
Pacifico Biolabs plans retail launches by late 2026. Mycelium-based protein products will reach supermarket shelves. This provides nutritious options. It supports broader environmental efforts. Food production’s impact must shrink. The company continuously refines its fermentation technology. Supply chain operations optimize for efficiency and reach. These preparations target widespread market adoption. Pacifico Biolabs aims for global impact, starting with Europe.
The company's innovative approach offers dual benefits. It fosters a circular economy model. It transforms underutilized assets into productive hubs. For breweries, this means new revenue. It diversifies their business models. It adapts to evolving market conditions. For consumers, it means accessible, sustainable protein. It offers a cleaner, greener choice. This strategy merges biotechnology with established industry. It creates a flexible manufacturing network. This supports future growth without massive new construction.
Europe's reliance on imported feed protein is a concern. Supply chains face environmental vulnerabilities. Geopolitical risks loom large. Pacifico Biolabs offers a domestic solution. Its protein is produced regionally. It shortens supply chains. It enhances food security. By utilizing existing brewery infrastructure, production costs decrease dramatically. The company aims for price parity. Mycelium protein seeks to compete directly with conventional meat products. This makes sustainable choices accessible to all. The vision is clear: high-quality, sustainable protein for a changing world.
Pacifico Biolabs champions a new era. It offers nutritious, sustainable protein. It contributes to global food system evolution. Environmental impact reduction is a core tenet. The company stands at the forefront. It redefines food production paradigms. This integration of European industrial infrastructure with biotechnology innovation is bold. It develops next-generation protein products. It ensures a more sustainable future for food. The future of food is fermenting. It is sustainable. It is here.
Berlin-based Pacifico Biolabs announced significant financing. A €7 million Series A round closed. This investment fuels ambitious expansion plans. The company accelerates its mycelium protein production platform. It solidifies its position in the rapidly expanding alternative protein market. This milestone marks a pivotal moment for the food technology startup. It prepares for a major commercial launch.
Pacifico Biolabs addresses critical food system challenges. Global demand for sustainable food grows. Resource-efficient production is paramount. The company develops protein products from mycelium. Mycelium forms the root-like structure of fungi. It is a powerful ingredient. A fermentation-based process is key. This biotechnology yields high-quality protein ingredients. It dramatically lowers environmental footprints. Traditional animal agriculture carries heavy costs. Mycelium protein requires less land. It uses less water. It emits fewer greenhouse gases. Pacifico Biolabs offers a superior path. It combines biotechnology with existing industrial assets. This creates scalable protein solutions. These solutions can meet future global food needs.
The newly secured capital drives core strategies. Production capabilities will expand. This leverages proprietary fermentation technology. The system operates within existing brewery facilities. This is a game-changing approach. Pacifico Biolabs avoids new construction. It partners with breweries. These facilities often possess idle fermentation capacity. Europe's beer consumption trends decline. Breweries seek new revenue streams. Pacifico Biolabs provides a symbiotic solution. It repurposes existing industrial assets. This model slashes capital expenditures. It shortens market timelines significantly. It enables swift deployment of sustainable protein. Products reach consumers faster. This is efficient industrial synergy.
The Series A round attracted a strategic group of investors. They focus on food innovation. Sustainability drives their decisions. Biotechnology represents their future vision. Stray Dog Capital joined the round. TGFS Technologiegründerfonds Sachsen invested. Sprout & About Ventures contributed. Simon Capital and FoodLabs also participated. A regional brewery partner demonstrated confidence. This syndicate underscores growing market interest. Technologies improving food system resilience are in demand. Environmental and supply chain challenges demand solutions. Pacifico Biolabs provides clear answers. Its technology promises a more secure food future.
Funding supports several strategic initiatives. These drive the company’s next growth phase. Increasing production capacity is primary. This focuses on scaling operations in Saxony, Germany. Expanding the workforce is critical. New talent will join R&D and commercial teams. Research and development efforts will strengthen. This enhances product formulation and process efficiency. Commercialization activities will advance across key European markets. The DACH region (Germany, Austria, Switzerland) is a primary focus. Nordic Europe also represents a vital target. These markets show strong consumer interest in sustainable food options.
Pacifico Biolabs plans retail launches by late 2026. Mycelium-based protein products will reach supermarket shelves. This provides nutritious options. It supports broader environmental efforts. Food production’s impact must shrink. The company continuously refines its fermentation technology. Supply chain operations optimize for efficiency and reach. These preparations target widespread market adoption. Pacifico Biolabs aims for global impact, starting with Europe.
The company's innovative approach offers dual benefits. It fosters a circular economy model. It transforms underutilized assets into productive hubs. For breweries, this means new revenue. It diversifies their business models. It adapts to evolving market conditions. For consumers, it means accessible, sustainable protein. It offers a cleaner, greener choice. This strategy merges biotechnology with established industry. It creates a flexible manufacturing network. This supports future growth without massive new construction.
Europe's reliance on imported feed protein is a concern. Supply chains face environmental vulnerabilities. Geopolitical risks loom large. Pacifico Biolabs offers a domestic solution. Its protein is produced regionally. It shortens supply chains. It enhances food security. By utilizing existing brewery infrastructure, production costs decrease dramatically. The company aims for price parity. Mycelium protein seeks to compete directly with conventional meat products. This makes sustainable choices accessible to all. The vision is clear: high-quality, sustainable protein for a changing world.
Pacifico Biolabs champions a new era. It offers nutritious, sustainable protein. It contributes to global food system evolution. Environmental impact reduction is a core tenet. The company stands at the forefront. It redefines food production paradigms. This integration of European industrial infrastructure with biotechnology innovation is bold. It develops next-generation protein products. It ensures a more sustainable future for food. The future of food is fermenting. It is sustainable. It is here.